2-anilino-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine | 403791-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-anilino-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine
• 英文别名: 4-(3-ethyl-2-methylimidazol-4-yl)-N-phenylpyrimidin-2-amine
• CAS: 403791-28-6
• 化学式: C₁₆H₁₇N₅
• 分子量: 279.344
• InChiKey: DAUUUCULWCEHGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-anilino-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine 在 氯磺酸 、 氯化亚砜 作用下， 反应 1.67h， 生成
  参考文献：
  名称：

  Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration

  摘要：

  该公式化合物（I）：其中R1、R2、R3、R4、R5、R6、p、q和n的定义如下，并描述了其药用盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为用于在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）作用的药物。

  公开号：

  US20040014776A1
• 作为产物：
  描述：

  5-(3-dimethylaminoprop-2-en-1-oyl)-1-ethyl-2-methylimidazole 、 苯基胍碳酸盐 在 sodium methylate 作用下， 以 2,4-滴二甲胺盐 为溶剂， 反应 18.0h， 以53%的产率得到2-anilino-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine
  参考文献：
  名称：

  [EN] DERIVATIVES OF 4- (IMIDAZOL-5-YL)-2-(4-SULFOANILINO) PYRIMIDINE WITH CDK INHIBITORY ACTIVITY
  [FR] DERIVES DE 4- (IMIDAZOL-5-YL)-2-(4-SULFOANILINO) PYRIMIDINE A ACTIVITE INHIBITRICE CDK

  摘要：

  公式（I）的化合物：其中R1、R2、R3、R4、R5和p的定义如下，并且描述了药学上可接受的盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为用于在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）效果的药物。

  公开号：

  WO2003076436A1

文献信息

• Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity
  申请人：Newcombe John Nicholas

  公开号：US20050131000A1

  公开（公告）日：2005-06-16

  Compounds of the formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  本文描述了化学式（I）的化合物，其中R1、R2、R3、R4、R5和p的定义如本文中所述，并描述了其药物学上可接受的盐和体内可水解的酯。同时还描述了它们的制备过程以及它们作为药物的用途，特别是作为产生对温血动物（如人）的细胞周期抑制（抗细胞增殖）效应的药物。
• Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
  申请人：Breault Anne Gloria

  公开号：US20060004033A1

  公开（公告）日：2006-01-05

  Compounds of the formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , p, q, and n are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  式(I)的化合物：其中R1、R2、R3、R4、R5、R6、p、q和n的定义如内部所述，并且所述化合物的药学上可接受的盐和体内可水解的酯被描述。还描述了它们的制备过程以及它们作为药物的用途，特别是作为在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）效应的药物。
• Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity
  申请人：AstraZeneca AB

  公开号：US07465728B2

  公开（公告）日：2008-12-16

  Compounds of the formula (I): wherein R1, R2, R3, R4, R5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5和p如定义所述，并描述了其药学上可接受的盐和体内可水解的酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为在温血动物（例如人）中产生细胞周期抑制（抗细胞增殖）效应的药物。
• Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
  申请人：Breault Gloria Anne

  公开号：US06969714B2

  公开（公告）日：2005-11-29

  Compounds of the formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , p, q, and n are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  该式(I)的化合物：其中R1、R2、R3、R4、R5、R6、p、q和n的定义如内部所述，并描述了其药学上可接受的盐和体内可水解的酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为制造细胞周期抑制（抗细胞增殖）效应的药物，用于温血动物，例如人类。
• IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION
  申请人：AstraZeneca AB

  公开号：EP1351958A1

  公开（公告）日：2003-10-15